Answers are grounded in this paper and cite their sources.
Assessment of serum short-chain fatty acid levels links to treatment response in myeloma, suggesting biomarkers for CAR-T therapy efficacy.
Supplementary Figure S21 shows the association between baseline (apheresis day) systemic short-chain fatty acid levels and treatment response in multiple myeloma patients. This figure analyzes serum SCFA levels at 100 and 180 days post–CAR T-cell infusion, comparing patients who achieved complete response to those who did not.
No takes yet. Share an insight, caveat, or question.
Uribe‐Herranz et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: